Read this company snapshot
Daily valuation snapshot
Kymera Therapeutics, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $112.4
- Market capitalization (USD)
- $9,346,129,463.2
- Price / earnings (TTM)
- Not reported
- Price / book
- 6.19
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KYMR in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research KYMR in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing KYMR with another company.
| Daily close (USD) | $112.4 |
| Market capitalization (USD) | $9,346,129,463.2 |
| Price / earnings (TTM) | Not reported |
| Price / book | 6.19 |
No matching rows. Clear the filter to see all records.
Read KYMR's valuation metrics
Company size
Kymera Therapeutics, Inc. Common Stock's recorded market capitalization is $9,346,129,463.2. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
KYMR's recorded price-to-book ratio is 6.19. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Kymera Therapeutics, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about KYMR. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow KYMR's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.